User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI

Primary tabs

Colliez, Florence [UCL] Fruytier, Anne-Catherine [UCL] Magat, Julie [UCL] Neveu, Marie-Aline [UCL] Cani, Patrice D. [UCL] Gallez, Bernard [UCL] Jordan, Bénédicte [UCL]

PURPOSE: To benchmark MOBILE (Mapping of Oxygen By Imaging Lipid relaxation Enhancement), a recent noninvasive MR method of mapping changes in tumor hypoxia, electron paramagnetic resonance (EPR) oximetry, and dynamic contrast-enhanced MRI (DCE-MRI) as biomarkers of changes in tumor hemodynamics induced by the antivascular agent combretastatin A4 (CA4). METHODS: NT2 and MDA-MB-231 mammary tumors were implanted subcutaneously in FVB/N and nude NMRI mice. Mice received 100 mg/kg of CA4 intraperitoneally 3 hr before imaging. The MOBILE sequence (assessing R1 of lipids) and the DCE sequence (assessing Ktrans hemodynamic parameter), were assessed on different cohorts. pO2 changes were confirmed on matching tumors using EPR oximetry consecutive to the MOBILE sequence. Changes in tumor vasculature were assessed using immunohistology consecutive to DCE-MRI studies. RESULTS: Administration of CA4 induced a significant decrease in lipids R1 (P = 0.0273) on pooled tumor models and a reduction in tumor pO2 measured by EPR oximetry. DCE-MRI also exhibited a significant drop of Ktrans (P < 0.01) that was confirmed by immunohistology. CONCLUSION: MOBILE was identified as a marker to follow a decrease in oxygenation induced by CA4. However, DCE-MRI showed a higher dynamic range to follow changes in tumor hemodynamics induced by CA4. Magn Reson Med, 2015. © 2015 Wiley Periodicals, Inc.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2016
Language Anglais
Journal information "Magnetic Resonance in Medicine" - Vol. 75, no. 2, p. 866-872 (2016)
Peer reviewed yes
Publisher Wiley ((United States) New York, NY)
issn 0740-3194
e-issn 1522-2594
Publication status Publié
Affiliation UCL - SSS/LDRI - Louvain Drug Research Institute
Links
  1. Mason Ralph P., Zhao Dawen, Liu Li, Trawick Mary Lynn, Pinney Kevin G., A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment, 10.1039/c0ib00135j
  2. Tozer Gillian M., Kanthou Chryso, Baguley Bruce C., Disrupting tumour blood vessels, 10.1038/nrc1628
  3. Lin, Mol Pharmacol, 34, 200 (1988)
  4. Salmon Beth A., Siemann Dietmar W., Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate, 10.1016/j.ijrobp.2006.12.051
  5. Nathan P., Zweifel M., Padhani A. R., Koh D.-M., Ng M., Collins D. J., Harris A., Carden C., Smythe J., Fisher N., Taylor N. J., Stirling J. J., Lu S.-P., Leach M. O., Rustin G. J. S., Judson I., Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer, 10.1158/1078-0432.ccr-11-3376
  6. Nagaiah Govardhanan, Remick Scot C, Combretastatin A4 phosphate: a novel vascular disrupting agent, 10.2217/fon.10.90
  7. Cai Sui, Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment, 10.2174/157489207779561462
  8. Cooney M. M., Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer, 10.1158/1078-0432.ccr-0364-3
  9. Ng Q.- S., Mandeville H., Goh V., Alonzi R., Milner J., Carnell D., Meer K., Padhani A. R., Saunders M. I., Hoskin P. J., Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck, 10.1093/annonc/mdr332
  10. Zweifel M., Jayson G. C., Reed N. S., Osborne R., Hassan B., Ledermann J., Shreeves G., Poupard L., Lu S.- P., Balkissoon J., Chaplin D. J., Rustin G. J. S., Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer, 10.1093/annonc/mdq708
  11. Siemann Dietmar W, Chaplin David J, Walicke Patricia A, A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P), 10.1517/13543780802691068
  12. Iversen Ane B., Busk Morten, Horsman Michael R., Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy, 10.3109/0284186x.2013.825050
  13. Dark, Cancer Res, 57, 1829 (1997)
  14. Murata Rumi, Siemann Dietmar W., Overgaard Jens, Horsman Michael R., Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors, 10.1016/s0167-8140(01)00384-x
  15. Ng Quan-Sing, Goh Vicky, Carnell Dawn, Meer Khalda, Padhani Anwar R., Saunders Michele I., Hoskin Peter J., Tumor Antivascular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Non–Small-Cell Lung Cancer, 10.1016/j.ijrobp.2006.11.028
  16. Murata Rumi, Overgaard Jens, Horsman Michael R, Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotheraphy, 10.1016/s0360-3016(01)01742-4
  17. Prokopiou E. M., Ryder S. A., Walsh J. J., Tumour vasculature targeting agents in hybrid/conjugate drugs, 10.1007/s10456-013-9347-8
  18. Horsman Michael R, Murata Rumi, Combination of vascular targeting agents with thermal or radiation therapy, 10.1016/s0360-3016(02)03926-3
  19. Zweifel Martin, Padhani Anwar R., Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?, 10.1007/s00259-010-1451-z
  20. Nielsen Thomas, Murata Rumi, Maxwell Ross J., Stødkilde-Jørgensen Hans, Østergaard Leif, Ley Carsten D., Kristjansen Paul E. G., Horsman Michael R., Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates, 10.3109/0284186x.2010.499135
  21. Galbraith Susan M., Maxwell Ross J., Lodge Martin A., Tozer Gillian M., Wilson John, Taylor N. Jane, Stirling J. James, Sena Luiza, Padhani Anwar R., Rustin Gordon J.S., Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging, 10.1200/jco.2003.05.187
  22. Maxwell Ross J., Wilson John, Prise Vivien E., Vojnovic Borivoj, Rustin Gordon J., Lodge Martin A., Tozer Gillian M., Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI, 10.1002/nbm.754
  23. Sunar Ulas, Makonnen Sosina, Zhou Chao, Durduran Turgut, Yu Guoqiang, Wang Hsing-Wen, Lee William M., Yodh Arjun G., Hemodynamic responses to antivascular therapy and ionizing radiation assessed by diffuse optical spectroscopies, 10.1364/oe.15.015507
  24. Zhao Dawen, Chang Cheng-Hui, Kim Jae G., Liu Hanli, Mason Ralph P., In Vivo Near-Infrared Spectroscopy and Magnetic Resonance Imaging Monitoring of Tumor Response to Combretastatin A-4-Phosphate Correlated With Therapeutic Outcome, 10.1016/j.ijrobp.2010.12.028
  25. Zhao Dawen, Jiang Lan, Hahn Eric W., Mason Ralph P., Tumor physiologic response to combretastatin A4 phosphate assessed by MRI, 10.1016/j.ijrobp.2005.03.009
  26. Jordan Bénédicte F., Magat Julie, Colliez Florence, Ozel Elif, Fruytier Anne-Catherine, Marchand Valérie, Mignion Lionel, Bouzin Caroline, Cani Patrice D., Vandeputte Caroline, Feron Olivier, Delzenne Nathalie, Himmelreich Uwe, Denolin Vincent, Duprez Thierry, Gallez Bernard, Mapping of oxygen by imaging lipids relaxation enhancement: A potential sensitive endogenous MRI contrast to map variations in tissue oxygenation : MRI Contrast to Map Variations in Tissue Oxygenation, 10.1002/mrm.24511
  27. Colliez, Proc Soc Int Magn Reson Med, 22, 3223 (2014)
  28. Colliez, Proc Soc Int Magn Reson Med, 22, 4750 (2014)
  29. Baudelet Christine, Gallez Bernard, Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: Comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes, 10.1016/j.mri.2004.02.005
  30. Gallez Bernard, Baudelet Christine, Jordan Bénédicte F., Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications, 10.1002/nbm.900
  31. Colliez F., Neveu M.-A., Magat J., Cao Pham T. T., Gallez B., Jordan B. F., Qualification of a Noninvasive Magnetic Resonance Imaging Biomarker to Assess Tumor Oxygenation, 10.1158/1078-0432.ccr-13-3434
  32. Ogawa S., Menon R.S., Tank D.W., Kim S.G., Merkle H., Ellermann J.M., Ugurbil K., Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model, 10.1016/s0006-3495(93)81441-3
  33. McPhail Lesley D., Griffiths John R., Robinson Simon P., Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging, 10.1016/j.ijrobp.2007.08.025
  34. El-Emir Ethaar, Boxer Geoffrey M., Petrie Ingrid A., Boden Robert W., Dearling Jason L.J., Begent Richard H.J., Pedley R. Barbara, Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice, 10.1016/j.ejca.2005.01.001
  35. Tofts Paul S., Brix Gunnar, Buckley David L., Evelhoch Jeffrey L., Henderson Elizabeth, Knopp Michael V., Larsson Henrik B.W., Lee Ting-Yim, Mayr Nina A., Parker Geoffrey J.M., Port Ruediger E., Taylor June, Weisskoff Robert M., Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbols, 10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s
  36. Fruytier A.-C., Magat J., Neveu M.-A., Karroum O., Bouzin C., Feron O., Jordan B., Cron G. O., Gallez B., Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4 : DCE-MRI WITH DIFFERENT CONTRAST AGENTS TO MONITOR THE EFFECT OF CA4, 10.1002/nbm.3220
  37. Zhao D., Richer E., Antich P. P., Mason R. P., Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI, 10.1096/fj.07-103713
  38. Abramson Richard G., Yankeelov Thomas E., Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials, Functional Imaging in Oncology (2014) ISBN:9783642404115 p.29-42, 10.1007/978-3-642-40412-2_2
  39. Li Junjie, Chen Feng, Feng Yuanbo, Cona Marlein Miranda, Yu Jie, Verbruggen Alfons, Zhang Jian, Oyen Raymond, Ni Yicheng, Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography, and Histopathology, 10.1593/tlo.12367
  40. Gaya A, Daley F, Taylor N J, Tozer G, Qureshi U, Padhani A, Pedley R B, Begent R, Wellsted D, Stirling J J, Rustin G, Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study, 10.1038/sj.bjc.6604426
Bibliographic reference Colliez, Florence ; Fruytier, Anne-Catherine ; Magat, Julie ; Neveu, Marie-Aline ; Cani, Patrice D. ; et. al. Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI. In: Magnetic Resonance in Medicine, Vol. 75, no. 2, p. 866-872 (2016)
Permanent URL http://hdl.handle.net/2078.1/162881